Menu Search
Equities

Champions Oncology Inc

2I3:DEU

Champions Oncology Inc

Actions
  • Price (EUR)3.94
  • Today's Change-0.32 / -7.51%
  • Shares traded0.00
  • 1 Year change-12.44%
  • Beta--
Data delayed at least 15 minutes, as of May 27 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Champions Oncology, Inc. is a technology-enabled research organization engaged in creating transformative technology solutions to be utilized in drug discovery and development. The Company's research center operates in both regulatory and non-regulatory environments and consists of a comprehensive set of computational and experimental research platforms. The Company’s TumorGraft Technology Platform (The Platform) provides select services to pharmaceutical and biotechnology companies. Its software as-a-service business is centered around its software platform and data tool, Lumin Bioinformatics (Lumin), which contains comprehensive information derived from its research services and clinical studies. Its drug discovery and development business leverage the computational and experimental capabilities within its platforms. Its discovery strategy utilizes its datacenter, coupled with artificial intelligence and other advanced computational analytics, to identify therapeutic targets.

  • Revenue in USD (TTM)49.22m
  • Net income in USD-9.73m
  • Incorporated1985
  • Employees230.00
  • Location
    Champions Oncology IncSUITE 619, 855 N. WOLFE STREETBALTIMORE 21205United StatesUSA
  • Phone+1 (410) 369-0365
  • Fax+1 (302) 636-5454
  • Websitehttps://championsoncology.com
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.